World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) will provide essential requirement for anyone who needs to keep up to date with epidemiological advances and new developments throughout the world, will encourage research, leadership and application of epidemiology of communicable and non-communicable disease
- Will evaluate all aspect of epidemiology
- Will publish original research and material concerned with study and improvement of epidemiological research worldwide
- Will aim all both fellow epidemiologist and those who use , epidemiological data
All articles published in World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) will be made freely accessible online immediately upon publication, without subscription charges Authors of articles published in World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) are the copyright holders of their articles and may granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article. The details can be found in the copyright section.
As World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) is an open access journal, therefore an article-processing charge of Rs. 10000/$250/€ 200/£175 will be levied on each article that is accepted for publication. The article processing charges for authors from low-income countries may be waived on discretion of the editorial board and publishers. Authors wishing to apply for these waivers should contact the editor.
World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) is a new journal and at present is index in google scholar and google, Journal is listed in Index Copernicus master journal list (ICV 79.41) and is under evaluation at present. it is being evaluated for inclusion by other indexing services as well.
Publication
Criteria for publication
World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) considers the following types of articles:
Research: manuscript reporting data from original research.
Case reports: reports of clinical cases that unreported cases, unusual side effects or drug interactions, new diseases or association of diseases, or new findings on pathogenesis and treatment of the disease.
Reviews: comprehensive, Systematic, authoritative, descriptions of any subject or meta anlaysis within the journal's scope.
Technical innovations: articles that describe a new test or procedure. The method described may either be completely new, or may offer a better version of an existing method. Ideally the authors should report on tested methods, however, the untested methods that may prove its value over time and hypothesis may also be considered.
Peer-review policies
World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) is supported by an expert
International Editorial Board.
Peer review is an important process of publication. World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515), aims to achieve a faster though high quality peer review to facilitate speedy publications. All articles submitted to the World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) will undergo a peer review. Reviewers will be selected from the database based on their expertise or after a detailed search of literature or may be suggested by the authors. The journal follows an electronic review process that facilitates faster publication. We attempt to complete the peer review process in 4-6 weeks. The journal will follow a closed review policy and hence the peer review reports will not be published along with the article until and unless the reviewers indicate this in their reports. The reviewing process will not be blinded.
All manuscripts considered for publication in World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515), will be with the understanding that the manuscript, or substantial parts of it, is not submitted to any other journal. Duplicate publications are generally discouraged, however, in special circumstances they may be considered if they are of exceptional and important content with acknowledgement to the original publication with permission of first publisher, and if the first article is published in language other than English. Manuscript that may have been deposited on a preprint server will be considered. Further information may be found on COPE and WAME servers. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Letter to the Editor or correspondence concerning the articles published in the journal will be considered and encouraged. Attempts will be made to link the correspondence to original article and have it indexed by the indexing services.
Narain Publishers Pvt. Ltd. (NPPL) follows and endorse the policy statements of Committee on Publication Ethics (COPE) and the World Association of Medical Editors (WAME) Policy Statement
World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) supports all initiatives aiming at improving the reporting of biomedical research. It is suggested that authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable.. Checklists are available for a number of study designs, including randomized controlled trials (CONSORT), systematic reviews (PRISMA), observational studies (STROBE), meta-analyses of observational studies (MOOSE), diagnostic accuracy studies (STARD) and qualitative studies (RATS). Authors of systematic review and meta analysis should follow the standards of reporting as detailed in Cochrane Reviewers' Handbook. Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies.
It is suggested that authors of protocols or reports on clinical trials, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (http://www.icmje.org/faq.html), the World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform. In the event of reporting on clinical trials the trial registration number should be included either in the title or in last line of abstract.
Details of the guideline on ethics of reporting the studies on human subjects and on animals are given
in the authors section.
Competing interests
World Journal Of Epidemiology and Cancer Prevention (ISSN 2321–3515) requires authors to declare any competing financial or other interest in relation to their work. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'. The details on the competing interests are given elsewhere.
